Regulatory approval

Published by the Health Canada. Approved

Health Canada approved dasatinib for the treatment of adults with Ph+ acute lymphoblastic leukemia (ALL) with resistance or intolerance to prior therapy.

This is written in the approval document as:

SPRYCEL (dasatinib) is indicated for the treatment of adults with Ph+ acute lymphoblastic leukemia (ALL) with resistance or intolerance to prior therapy.

Citation

Bristol-Myers Squibb Canada. Sprycel (dasatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080799.PDF. Revised June 2025. Accessed April 2026.

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HC (1)	BCR::ABL1	Acute Lymphoblastic Leukemia	Dasatinib

Contributions

Date	Contributor	Description
2024-10-30	Van Allen lab	Initial access of FDA approvals